Hims & Hers Health Is Looking to Cash In on This Novo Nordisk Blunder
Source: Motley Fool
2025-07-16 08:45:00 ET
Hims & Hers Health (NYSE: HIMS) is a top telehealth stock that has been growing its business rapidly in recent years. And one of the ways it has done that is by expanding into new markets and reaching a broader range of customers.
Recently, it's looking to take advantage of an opportunity that has opened up as a result of a costly mistake that drugmaker Novo Nordisk (NYSE: NVO) has made. After failing to pay a maintenance fee, the patent on semaglutide will run out in Canada as early as next year. And Hims & Hers is looking to capitalize on that.
Image source: Getty Images.
Hims & Hers Health Inc. Class A
NASDAQ: HIMS
HIMS Trading
-4.45% G/L:
$23.94 Last:
26,336,499 Volume:
$24.07 Open:
HIMS Latest News
HIMS Stock Data
$3,941,734,020
205,134,076
0.02%
209
N/A
Consumer Products - Household & Personal
Consumer Staples
US
San Francisco
